|
|
|
| Research progress of pyroptosis and PCSK9 in atherosclerosis |
| ZHANG Liang LI Jing |
| Department of Cardiovascular, Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Hubei Province, Wuhan 430064, China |
|
|
|
Abstract Atherosclerosis (AS) is the pathological basis of a variety of cardiovascular and cerebrovascular diseases, while seriously threatens human health and safety. The pathogenesis of AS is not yet fully understood. The latest research found that the occurrence and development of AS is closely related to the proprotein convertase subtilisin kexin type 9 (PCSK9) and pyrolysis. This article reviews PCSK9 and pyrolysis in atherosclerosis and the clinical application progress of PCSK9 inhibitors.
|
|
|
|
|
|
[1] Fink SL，Cookson BT. Pillars Article：Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages [J]. Cell Microbiol，2006， 8（11）：1812-1825.
[2] He Y，Hara H，Nú?觡ez G. Mechanism and Regulation of NLRP3 Inflammasome Activation [J]. Trends Biochem Sci，2016，41（12）：1012-1021.
[3] Heilig R，Broz P. Function and mechanism of the pyrin inflammasome [J]. Eur J Immunol，2018，48（2）：230-238.
[4] Ruan J. Structural Insight of Gasdermin Family Driving Pyroptotic Cell Death [J]. Adv Exp Med Biol，2019，1172：189-205.
[5] Yang J，Zhao Y，Shao F. Non-canonical activation of inflammatory caspases by cytosolic LPS in innate immunity [J]. Curr Opin Immunol，2015，32：78-83.
[6] Cheng KT，Xiong SQ，Ye ZM，et al. Caspase-11-mediated endothelial pyroptosis underlies endotoxemia-induced lung injury [J]. J Clin Invest，2017，127（11）：4124-4135.
[7] Yi YS. Functional crosstalk between non-canonical caspase-11 and canonical NLRP3 inflammasomes during infection-mediated inflammation [J]. Immunology，2020，159（2）：142-155.
[8] Yin Y，Li XY，Sha XJ，et al. Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway [J]. Arterioscler Thromb Vasc Biol，2015，35（4）：804-816.
[9] Deng YP，Han X，Yao Z，et al. PPARα Agonist Stimulated Angiogenesis by Improving Endothelial Precursor Cell Function Via a NLRP3 Inflammasome Pathway [J]. Cell Physiol Biochem，2017，42（6）：2255-2266.
[10] Pan JY，Lu L，Wang XY，et al. AIM2 regulates vascular smooth muscle cell migration in atherosclerosis [J]. Biochem Biophys Res Commun，2018，497（1）：401-409.
[11] Lopez-Pastrana J，Ferrer LM，Li YF，et al. Inhibition of Caspase-1 Activation in Endothelial Cells Improves Angiogenesis：a novel therapeutic potential for ischemia [J]. J Biol Chem，2015，290（28）：17485-17494.
[12] Wu XX，Zhang HY，Qi W，et al. Nicotine promotes atherosclerosis via ROS-NLRP3-mediated endothelial cell pyroptosis [J]. Cell Death Dis，2018，9（2）：171.
[13] Xu YJ，Zheng L，Hu YW，et al. Pyroptosis and its relationship to atherosclerosis [J]. Clin Chim Acta，2018， 476：28-37.
[14] Tumurkhuu G，Dagvadorj J，Porritt RA，et al. Chlamydia pneumoniae Hijacks a Host Autoregulatory IL-1β Loop to Drive Foam Cell Formation and Accelerate Atherosclerosis [J]. Cell Metab，2018，28（3）：432-448.e4.
[15] Sieve I，Ricke-Hoch M，Kasten M，et al. A positive feedback loop between IL-1β，LPS and NEU1 may promote atherosclerosis by enhancing a pro-inflammatory state in monocytes and macrophages [J]. Vascul Pharmacol，2018，103（105）：16-28.
[16] Lin J，Shou XL，Mao XB，et al. Oxidized low density lipoprotein induced caspase-1 mediated pyroptotic cell death in macrophages： implication in lesion instability? [J]. PLoS One，2013，8（4）：e62148.
[17] Ye Z，Yao YA，Ji B，et al. Sirt6-induced autophagy restricted TREM-1-mediated pyroptosis in ox-LDL-treated endothelial cells：relevance to prognostication of patients with acute myocardial infarction [J]. Cell Death Discov，2019，5：88.
[18] Ultsch M，Li W，Eigenbrot C，et al. Identification of a Helical Segment within the Intrinsically Disordered Region of the PCSK9 Prodomain [J]. J Mol Biol，2019，431（5）：885-903.
[19] Giunzioni I，Tavori H，Covarrubias R，et al. Local effects of human PCSK9 on the atherosclerotic lesion [J]. J Pathol，2016，238（1）：52-62.
[20] Cheng JM，Oemrawsingh RM，Garcia-Garcia HM，et al. PCSK9 in relation to coronary plaque inflammation：Results of the atheroremoivus study [J]. Atherosclerosis，2016，248：117-122.
[21] Ding ZF，Pothineni NVK，Goel A，et al. PCSK9 and inflammation：Role of shear stress，pro-inflammatory cytokines and LOX-1 [J]. Cardiovasc Res，2019，12（20）：125-137.
[22] Tang ZH，Peng J，Ren Z，et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway [J]. Atherosclerosis，2017，262：113-122.
[23] Kong FQ，Ye BZ，Cao JT，et al. Curcumin Represses NLRP3 Inflammasome Activation via TLR4/MyD88/NF-κB and P2X7R Signaling in PMA-Induced Macrophages [J]. Front Pharmacol，2016，7：369.
[24] Bernelot Moens SJ，Neele AE，Kroon J，et al. PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia [J]. Eur Heart J，2017，38（20）：1584-1593.
[25] Winter C，Silvestre-Roig C，Ortega-Gomez A，et al. Chrono-pharmacological Targeting of the CCL2-CCR2 Axis Ameliorates Atherosclerosis [J]. Cell Metab，2018，28（1）：175-182.e5.
[26] Geng ZH，Xu F，Zhang YG. MiR-129-5p-mediated Beclin-1 suppression inhibits endothelial cell autophagy in atherosclerosis [J]. Am J Transl Res，2016，8（4）：1886-1894.
[27] Szarek M，Steg PG，DiCenso D，et al. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the Odyssey Outcomes Trial [J]. Circ Cardiovasc Qual Outcomes，2019，12（11）：e005858.
[28] Moriarty PM，Thompson PD，Cannon CP，et al. Efficacy and safety of alirocumab in statin-intolerant patients over 3 years：open-label treatment period of the odyssey alternative trial [J]. J Clin Lipidol，2020，14（1）：88-97.e2.
[29] Mu GY，Xiang Q，Zhou S，et al. Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk：An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials [J]. Adv Ther，2020，2（27）：98-110.
[30] Cao YX，Li S，Liu HH，et al. Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels：a systematic review and meta-analysis of randomised controlled trials [J]. BMJ Open，2018，8（9）：e022348.
[31] 吴娜琼，刘硕霖，石惠薇.ESC动脉粥样硬化和血管生物学工作组确定降脂治疗中伴随的抗炎反应立场性文件解读[J].中国循环杂志，2019，34（S1）：60-65. |
|
|
|
